Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-Beta Asset to Portfolio

Bristol Myers Squibb and Forbius have announced that they have entered into a definitive agreement under which Bristol Myers Squibb will acquire Forbius. Forbius has developed a portfolio of highly selective and potent inhibitors of TGF-beta 1 & 3, which are key mediators of immunosuppression and fibrosis.